Copyright
©The Author(s) 2004.
World J Gastroenterol. Jul 1, 2004; 10(13): 1893-1897
Published online Jul 1, 2004. doi: 10.3748/wjg.v10.i13.1893
Published online Jul 1, 2004. doi: 10.3748/wjg.v10.i13.1893
Table 1 Characteristics of SENV positive and SENV negative patients
| SENV positive (n = 21) | SENV negative (n = 74) | P value | |
| Median age (yr) | 42 ± 12 | 42 ± 12 | 0.991 |
| Male, m (%) | 13 (62%) | 46 (62%) | 1.002 |
| Median baseline ALT (IU/L ) | 81 ± 109 | 69 ± 60 | 0.561 |
| Pretreated, n (%) | 3 (14%) | 10 (14%) | 1.002 |
| Hepatitis C genotype, n (%) | |||
| 1, 4 | 16 (76%) | 51 (69%) | 0.602 |
| 2, 3 | 5 (24%) | 21 (28%) | 0.792 |
| Undetermined | 0 (0%) | 2 (3%) | |
| PEG-IFN | 11 (52%) | 35 (47%) | 0.812 |
| Sustained HCV response to therapy | 11 (52%) | 37 (50%) | 1.002 |
Table 2 Clinical, biochemical and viral characteristics in rela-tion to HCV response to combination therapy
| Sustained response (n = 48) | No sustained response (n = 47) | P value | |
| Male, n (%) | 30 (63%) | 29 (62%) | 0.341 |
| Age (yr ) | 39 ± 11 | 45 ± 11 | < 0.012 |
| ALT | 70 ± 78 | 74 ± 68 | 0.542 |
| HCV genotype, n (%) | |||
| 1 or 4 | 30 (63%) | 37 (79%) | |
| 2 or 3 | 16 (33%) | 10 (21%) | 0.161 |
| Undetermined | 2 (4%) | ||
| SEN positive, n (%) | 10 (21%) | 11 (23%) | 0.811 |
| SENV H-DNA | 393 ± 297 | 523 ± 452 | 0.482 |
| (copies/mL) |
Table 3 Clinical and virological characteristics of patients coinfected with HCV and SENV
| No | Age (yr) | SEX | ALT (U/L) | HCV | SENV | SENV H | HCV | SEN V |
| genotype | genotype | copies/mL | response | response | ||||
| 1 | 60 | M | 62 | 1 | H | 218 | Yes | Yes |
| 2 | 47 | F | 26 | 1 | D/H | 74 | No | Yes |
| 3 | 41 | F | 41 | 1 | D | - | Yes | No |
| 4 | 31 | M | 26 | 1 | H | 208 | Yes | Yes |
| 5 | 59 | F | 62 | 1 | H | 1304 | No | No |
| 6 | 47 | F | 169 | 2 | H | 1184 | No | No |
| 7 | 31 | M | 26 | 1 | H | 484 | Yes | No |
| 8 | 28 | M | 32 | 1 | H | 308 | Yes | Yes |
| 9 | 63 | M | 168 | 1 | H | 310 | No | No |
| 10 | 59 | F | 121 | 4 | H | 338 | No | Yes |
| 11 | 35 | F | 42 | 2 | H | 38 | Yes | Yes |
| 12 | 36 | M | 43 | 1 | H | 532 | No | Yes |
| 13 | 41 | M | 24 | 1 | H | 848 | Yes | Yes |
| 14 | 41 | M | 180 | 1 | D | - | Yes | Yes |
| 15 | 32 | F | 513 | 3 | H | 224 | Yes | Yes |
| 16 | 44 | F | 36 | 3 | D | - | Yes | Yes |
| 17 | 28 | M | 28 | 2 | H | 814 | Yes | Yes |
| 18 | 42 | M | 40 | 1 | H | 74 | No | Yes |
| 19 | 37 | M | 32 | 4 | H | 230 | No | Yes |
| 20 | 62 | F | 41 | 1 | H | 662 | No | Yes |
Table 4 Clinical and virological parameter of SENV re-sponse to combination therapy in 20 HCV/SENV-coinfected patients
- Citation: Sagir A, Adams O, Kirschberg O, Erhardt A, Heintges T, Häussinger D. SEN virus does not affect treatment response in hepatitis C virus coinfected patients but SEN virus response depends on SEN virus DNA concentration. World J Gastroenterol 2004; 10(13): 1893-1897
- URL: https://www.wjgnet.com/1007-9327/full/v10/i13/1893.htm
- DOI: https://dx.doi.org/10.3748/wjg.v10.i13.1893
